$PRDS News
Last published 3y ago
- 3y agoPRDSPardes Biosciences Announces Closing of Tender OfferGlobeNewswireCARLSBAD, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS) (Pardes or the Company) today announced that MediPacific, Inc. (MediPacific), an affiliate of Foresite Capital, through its
- 3y agoPRDSMediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences SharesBusiness WireAs previously announced, on July 16, 2023, MediPacific Sub, Inc. ("Purchaser") and MediPacific, Inc. ("Parent"), affiliates of Foresite Capital, entered into a definitive agreement and plan of merger (the "Merger
- 3y agoFRGIPRDSSCUVRTVMoore Kuehn Encourages FRGI, VRTV, SCU, and PRDS Investors to Contact Law FirmGlobeNewswireNEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoAMNBNLTXPRDSSCUMoore Kuehn Encourages PRDS, AMNB, NLTX, and SCU Investors to Contact Law FirmPR NewswireNEW YORK, Aug. 3, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following
- 3y agoAMNBNLTXPRDSSCUMoore Kuehn Encourages AMNB, SCU, NLTX, and PRDS Investors to Contact Law FirmGlobeNewswireNEW YORK, July 26, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoPRDSPardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value RightsGlobeNewswireCARLSBAD, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS) today announced that it has entered into a definitive merger agreement whereby MediPacific, Inc. (Purchaser) will acquire
- 3y agoPRDSPardes Biosciences Reports First Quarter 2023 Financial ResultsGlobeNewswireCARLSBAD, Calif., May 05, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS) today reported financial results for the first quarter ended March 31, 2023. "As previously announced this year, Pardes
- 3y agoPRDSPardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19GlobeNewswirePomotrelvir did not meet the primary endpoint measured by proportion of participants below the limit of detection for infectious SARS-CoV-2 on day 3 of treatment with pomotrelvir vs. placebo Otherwise healthy,
- 3y agoPRDSPardes Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateGlobeNewswireData from ongoing Phase 2 trial evaluating pomotrelvir (formerly known as PBI-0451) for the treatment of COVID-19 expected in the coming weeks Cash to fund operations for the next twelve months CARLSBAD, Calif., March
- 3y agoPRDSPardes Biosciences to Present at SVB Securities Global Biopharma ConferenceGlobeNewswireCARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acting, oral antiviral
- 3y agoASMBPRDSCarver Biosciences Announces Appointment of Three Members to its Scientific Advisory BoardBusiness WireCarver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB). Cameron Myhrvold Ph.D., co-founder of Carver will
- 4y agoPRDSPardes Biosciences Reports Third Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswireCARLSBAD, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug candidate for the
- 4y agoPRDSPardes Biosciences to Present at Jefferies London Healthcare ConferenceGlobeNewswireCARLSBAD, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acting, oral antiviral
- 4y agoPRDSPardes Biosciences Appoints Laurie Smaldone Alsup, M.D. and John C. Pottage, Jr., M.D. to Board of DirectorsGlobeNewswireCARLSBAD, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel oral antiviral drug candidate for the treatment and prevention
- 4y agoPRDSPardes Biosciences Announces Commencement of Phase 2 Trial Evaluating PBI-0451 for the Treatment of SARS-CoV-2 InfectionsGlobeNewswirePhase 2 trial expected to enroll 210 patients at approximately 75 sites to evaluate antiviral activity, safety, and efficacy of PBI-0451 versus placebo Interim data from Phase 2 anticipated in Q1 2023 CARLSBAD, Calif., Sept. 13, 2022 (GLOBE NEWSW
- 4y agoPRDSPardes Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewswireCARLSBAD, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel direct-acting, oral antiviral drug candidate for the treatment
- 4y agoPRDSPardes Biosciences Reports Second Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswireCARLSBAD, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2
- 4y agoPRDSPardes Biosciences to Present at Jefferies Global Healthcare ConferenceGlobeNewswireCARLSBAD, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acting, oral antiviral drug candidate for the treatment a
- 4y agoPRDSPardes Biosciences Reports First Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswireCARLSBAD, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acting, oral antiviral drug candidate for the treatment an
- 4y agoPRDSPardes Biosciences Reports Full Year 2021 Financial Results and Provides Business UpdateGlobeNewswireCARLSBAD, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acting, oral antiviral drug candidate for the treatment
- 4y agoPRDSPardes Biosciences to Present at the International Conference On Antiviral Research 2022GlobeNewswireCARLSBAD, Calif. , March 21, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel direct-acting, oral antiviral drug candidate for the treatment a
- 4y agoPRDSPardes Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCARLSBAD, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel direct-acting, oral antiviral drug candidate for the treatment an
- 4y agoPRDSPardes Biosciences to Present at Cowen Healthcare ConferenceGlobeNewswireCARLSBAD, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel direct-acting, oral antiviral drug candidate for the treatment an
- 4y agoPRDSPardes Biosciences Appoints Thomas G. Wiggans to CEO and Chairman of the BoardGlobeNewswireMr. Wiggans brings over 40 years of biopharmaceutical industry experience, including over 25 years in chief executive leadership roles with multiple successful acquisitions. His expertise will be beneficial to Pardes as the company rapidly progresses to
- 4y agoPRDSPardes Biosciences Presents Interim Clinical Data from Ongoing PBI-0451 Phase 1 Trial Supporting the Potential of PBI-0451 as a Stand-Alone Oral Regimen for COVID-19 at Conference on Retroviruses and Opportunistic Infections 2022GlobeNewswirePBI-0451 administered twice-daily as a stand-alone agent achieves and maintains PK exposures anticipated to provide potent antiviral activity against SARS-CoV-2 PBI-0451 has been generally well-tolerated and has shown good oral bioavailability Com
- 4y agoPRDSPardes Biosciences to Host Virtual Investor EventGlobeNewswireCARLSBAD, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and preventio
- 4y agoPRDSPardes Biosciences to Present Clinical Data from Ongoing PBI-0451 Phase 1 Trial at Conference On Retroviruses And Opportunistic Infections 2022GlobeNewswireCARLSBAD, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and preventio
- 4y agoPRDSPardes Biosciences Announces FDA Clearance of IND Application for PBI-0451, an Oral Antiviral Drug Candidate for the Treatment and Prevention of SARS-CoV-2 InfectionsGlobeNewswireCARLSBAD, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and preventio
- 4y agoPRDSPardes Biosciences to Present at J.P. Morgan Healthcare ConferenceGlobeNewswireCARLSBAD, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and preventio